CHARLESTON, S.C. and DEERFIELD, Ill., July 25, 2024 /PRNewswire/ -- MUSC Hollings Cancer Center, an NCI-designated cancer center within the Medical University of South Carolina (MUSC), the state's only comprehensive academic health system, is partnering with MOLLI Surgical to adopt the MOLLI® 2 System. The award-winning wire-free and radiation-free technology for localizing lesions for breast cancer surgery improves the patient experience and has earned praise from surgeons for its accuracy and ease of use.
"Hollings has adopted the MOLLI 2 System in order to treat our patients with the most accurate, advanced technology available," said Andrea Abbott, M.D., a surgical oncologist and medical director of the Comprehensive Breast Program at Hollings. "MOLLI 2 provides precise feedback while localizing the lesion; the information is instantaneous and allows for efficiency and accuracy. And patients appreciate the flexibility of having the MOLLI® Marker placed ahead of time instead of adding another procedure to the day of surgery."
The MOLLI 2 System is an innovative technology that allows radiologists to mark lesions with the MOLLI Marker, a localization device roughly the size of a sesame seed. The device can be placed up to 30 days before surgery, allowing radiology to make the best use of time in the mammography suite without the need to synchronize schedules with surgery. Surgeons then use the MOLLI® Wand and MOLLI® Tablet to locate the lesion marked in radiology reliably, eliminating the need for wire-guided localization. The technology features a market-leading innovation — directional 3D guidance — which enables MOLLI 2 to direct surgeons to the lesion with millimeter precision. The MOLLI 2 System is easy to use, reliable, and precise, improving efficiency and enhancing the patient experience.
"MUSC makes a profound impact on its community as the state's only comprehensive academic health system. Given its wide reach to patients and medical students, we're honored to be selected as a partner to provide precision surgery solutions," said Ananth Ravi, President and CEO of MOLLI Surgical. "MUSC's dedication to advancing patient-centric breast cancer care is further affirmed by their adoption of MOLLI 2."
Team members at Hollings have found it easy to integrate the MOLLI 2 System into their existing workflows and operating rooms. "There was essentially no learning curve to implement MOLLI 2 and begin using it in the operating room. The device setup was simple and easy for everyone; the physicians, the OR staff, and the radiology team were all able to quickly add MOLLI 2 into their patient care," said Dr. Abbott.